Prevalence, Incidence and Mortality of Chronic Kidney Disease in Type 1 and Type 2 Diabetes—A Nationwide Danish Register-Based Cohort Study.
People with diabetes live longer with kidney disease than before, yet kidney disease death remains worryingly high despite new drugs.
This comprehensive nationwide Danish registry study tracked chronic kidney disease trends in people with type 1 and type 2 diabetes over 2016–2024, showing a paradox of declining CKD incidence alongside rising prevalence, likely reflecting longer survival with CKD due to improved treatment. Despite therapeutic advances (including GLP-1 and SGLT2 agents), CKD mortality remained markedly elevated, underscoring ongoing clinical burden and need for earlier detection and prevention.
What the study was
- Study design
- nationwide register-based cohort study (Denmark, 2016–2024)
- Category
- Prevention
- Maturity
- Validated
- Journal
- Diabetes, Obesity and Metabolism
Why it surfaced
Nationwide longitudinal data on CKD burden trends in diabetes over 8 years, directly tracking the population-level impact of cardiometabolic therapies; critical context for T7 GLP-1/SGLT2 and cardiorenal risk watchlist.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.